These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29167315)

  • 1. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.
    Song S; Xie M; Scott AW; Jin J; Ma L; Dong X; Skinner HD; Johnson RL; Ding S; Ajani JA
    Mol Cancer Ther; 2018 Feb; 17(2):443-454. PubMed ID: 29167315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties.
    Song S; Ajani JA; Honjo S; Maru DM; Chen Q; Scott AW; Heallen TR; Xiao L; Hofstetter WL; Weston B; Lee JH; Wadhwa R; Sudo K; Stroehlein JR; Martin JF; Hung MC; Johnson RL
    Cancer Res; 2014 Aug; 74(15):4170-82. PubMed ID: 24906622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
    Li F; Xu Y; Liu B; Singh PK; Zhao W; Jin J; Han G; Scott AW; Dong X; Huo L; Ma L; Pizzi MP; Wang Y; Li Y; Harada K; Xie M; Skinner HD; Ding S; Wang L; Krishnan S; Johnson RL; Song S; Ajani JA
    Clin Cancer Res; 2019 Apr; 25(7):2264-2277. PubMed ID: 30563933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.
    Song S; Honjo S; Jin J; Chang SS; Scott AW; Chen Q; Kalhor N; Correa AM; Hofstetter WL; Albarracin CT; Wu TT; Johnson RL; Hung MC; Ajani JA
    Clin Cancer Res; 2015 Jun; 21(11):2580-90. PubMed ID: 25739674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma.
    Xu Y; Li Y; Jin J; Han G; Sun C; Pizzi MP; Huo L; Scott A; Wang Y; Ma L; Lee JH; Bhutani MS; Weston B; Vellano C; Yang L; Lin C; Kim Y; MacLeod AR; Wang L; Wang Z; Song S; Ajani JA
    Mol Cancer; 2019 Oct; 18(1):141. PubMed ID: 31601234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotine activates YAP1 through nAChRs mediated signaling in esophageal squamous cell cancer (ESCC).
    Zhao Y; Zhou W; Xue L; Zhang W; Zhan Q
    PLoS One; 2014; 9(3):e90836. PubMed ID: 24621512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
    Ota M; Sasaki H
    Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth.
    Maruyama J; Inami K; Michishita F; Jiang X; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Miyamura N; Hirayama J; Nishina H; Nogawa D; Yamamoto K; Hata Y
    Mol Cancer Res; 2018 Feb; 16(2):197-211. PubMed ID: 29061667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
    Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
    Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.
    Kandasamy S; Adhikary G; Rorke EA; Friedberg JS; Mickle MB; Alexander HR; Eckert RL
    Mol Cancer Res; 2020 Mar; 18(3):343-351. PubMed ID: 31732616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
    Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y
    Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells.
    Bora-Singhal N; Nguyen J; Schaal C; Perumal D; Singh S; Coppola D; Chellappan S
    Stem Cells; 2015 Jun; 33(6):1705-18. PubMed ID: 25754111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1.
    Zhang H; Ramakrishnan SK; Triner D; Centofanti B; Maitra D; Győrffy B; Sebolt-Leopold JS; Dame MK; Varani J; Brenner DE; Fearon ER; Omary MB; Shah YM
    Sci Signal; 2015 Oct; 8(397):ra98. PubMed ID: 26443705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gli1 interacts with YAP1 to promote tumorigenesis in esophageal squamous cell carcinoma.
    Wang C; Cheng L; Song S; Wu S; Sun G
    J Cell Physiol; 2020 Nov; 235(11):8224-8235. PubMed ID: 31957872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
    Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
    J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
    Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
    EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis.
    Kang W; Tong JH; Chan AW; Lee TL; Lung RW; Leung PP; So KK; Wu K; Fan D; Yu J; Sung JJ; To KF
    Clin Cancer Res; 2011 Apr; 17(8):2130-9. PubMed ID: 21346147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
    Chang HL; Chen HA; Bamodu OA; Lee KF; Tzeng YM; Lee WH; Tsai JT
    Toxicol In Vitro; 2018 Sep; 51():74-82. PubMed ID: 29698666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.